Serum paraoxonase activity and phenotype distribution in Turkish subjects with coronary heart disease and its relationship to serum lipids and lipoproteins

被引:35
作者
Karakaya, A [1 ]
Ibis, S
Kural, T
Köse, SK
Karakaya, AE
机构
[1] Ankara Univ, Fac Pharm, Dept Toxicol, TR-06100 Ankara, Turkey
[2] Directorate Pharmaceut, Minist Hlth, Ankara, Turkey
[3] Ankara Yuksek Ihtisas Hosp, Dept Cardiovasc Dis, Ankara, Turkey
[4] Ankara Univ, Kikimevi Hlth Technol High Sch, TR-06100 Ankara, Turkey
[5] Gazi Univ, Fac Pharm, Dept Toxicol, TR-06330 Ankara, Turkey
关键词
paraoxonase; high-density lipoprotein; coronary heart disease;
D O I
10.1016/S0009-2797(99)00085-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recently, biochemical studies of paraoxonase in the serum of humans have shown that much of this enzymes' activity is associated with high-density lipoprotein (HDL) and paraoxonase may play a role in lipid metabolism preventing the accumulation of the lipoperoxides. In this study, a possible relationship between coronary heart disease (CHD) and paraoxonase activity were investigated. Serum triglycerides, total cholesterol, HDL-cholesterol and paraoxonase activity were measured in unrelated healthy donors and CHD patients. It was found that paraoxonase activity was trimodally distributed in both groups but no statistically significant difference was found between phenotype distributions of controls and CHD patients (gene frequencies; 0.632 and 0.382 of controls, 0.702 and 0.298 of patients for the A and B alleles, respectively). However, in CHD group, a high possibility was found to be phenotype A compared with the control group. A relative risk of 1.48 (95% confidence intervals (CI)? 0.986-2.227) was found for the relation between CHD and the paraoxonase activity. Patients' HDL-cholesterol values were lower and triglycerides were higher than controls (P < 0.001). It may be concluded from the present study that although no statistically significant difference was found between paraoxonase phenotype distributions of controls and CHD patients, a decrease in paraoxonase activity could become a risk factor for this disease. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:193 / 200
页数:8
相关论文
共 35 条
[1]   SERUM PARAOXONASE ACTIVITY, CONCENTRATION, AND PHENOTYPE DISTRIBUTION IN DIABETES-MELLITUS AND ITS RELATIONSHIP TO SERUM-LIPIDS AND LIPOPROTEINS [J].
ABBOTT, CA ;
MACKNESS, MI ;
KUMAR, S ;
BOULTON, AJ ;
DURRINGTON, PN .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (11) :1812-1818
[2]  
ADKINS S, 1993, AM J HUM GENET, V52, P598
[3]   The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns [J].
Antikainen, M ;
Murtomaki, S ;
Syvanne, M ;
Pahlman, R ;
Tahvanainen, E ;
Jauhiainen, M ;
Frick, MH ;
Ehnholm, C .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (04) :883-885
[4]   Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities - Selective action of human paraoxonase allozymes Q and R [J].
Aviram, M ;
Billecke, S ;
Sorenson, R ;
Bisgaier, C ;
Newton, R ;
Rosenblat, M ;
Erogul, J ;
Hsu, C ;
Dunlop, C ;
La Du, B .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (10) :1617-1624
[5]   Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions - A possible peroxidative role for paraoxonase [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS ;
Primo-Parmo, SL ;
La Du, BN .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (08) :1581-1590
[6]  
ECKERSON HW, 1983, AM J HUM GENET, V35, P214
[7]  
Garin M.C., 1997, J CLIN INVEST, V99, P62
[8]   CHARACTERIZATION OF PARAOXONASE ACTIVITY IN PERICARDIAL FLUID - USEFULNESS AS A MARKER OF CORONARY-DISEASE [J].
HERNANDEZ, AF ;
PLA, A ;
VALENZUELA, A ;
GIL, F ;
VILLANEUVA, E .
CHEMICO-BIOLOGICAL INTERACTIONS, 1993, 87 (1-3) :173-177
[9]   The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study [J].
Herrmann, SM ;
Blanc, H ;
Poirier, O ;
Arveiler, D ;
Luc, G ;
Evans, A ;
MarquesVidal, P ;
Bard, JM ;
Cambien, F .
ATHEROSCLEROSIS, 1996, 126 (02) :299-303
[10]   THE MOLECULAR-BASIS OF THE HUMAN SERUM PARAOXONASE ACTIVITY POLYMORPHISM [J].
HUMBERT, R ;
ADLER, DA ;
DISTECHE, CM ;
HASSETT, C ;
OMIECINSKI, CJ ;
FURLONG, CE .
NATURE GENETICS, 1993, 3 (01) :73-76